Vietnam Delays GMP Compliance For Two More Years
This article was originally published in PharmAsia News
Vietnam has decided to put off Good Manufacturing Practices requirements until 2010 instead of ordering them this month as planned. The Ministry of Health acted after pharmaceutical industry representatives appealed for more time because of the high cost many face in having to comply with the GMP standards. The head of Central 2 Pharmaceutical, which is compliant, said it had to spend $7 million over two years to change its factory and production line to meet the standards. He said many other companies would have great difficulty in raising the money needed to comply. (Click here for more
You may also be interested in...
The US FDA’s Circulatory System Devices advisory panel will meet on 27 October to discuss the review of the premarket approval application of Neovasc’s Reducer device, which is intended to treat angina. See what Neovasc’s CEO Fred Colen said about it here.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Appropriators’ FDA FY 2021 budget includes amendment to expand its mandatory recall authority introduced by chairman of subcommittee with oversight of agency’s budget, Rep. Sanford Bishop. He said the agency should be able to force drug product recalls as it already can for vaccines, medical devices and products containing ingredients also scheduled as controlled substances.